Anthony James Culverwell - 21 Aug 2025 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Director
Signature
/s/ Anthony James Culverwell
Issuer symbol
QNRX
Transactions as of
21 Aug 2025
Net transactions value
$0
Form type
4
Filing time
25 Aug 2025, 16:05:52 UTC
Previous filing
03 Jun 2025
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Culverwell Anthony James Director C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN /s/ Anthony James Culverwell 25 Aug 2025 0001693548

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNRX Share Option (Right to Buy) Award $0 +13,682 $0.000000 13,682 21 Aug 2025 ADS 13,682 $9.07 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
F2 The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.
F3 The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.